{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:40:23Z","timestamp":1775742023810,"version":"3.50.1"},"reference-count":92,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.rdc.2022.08.003","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T18:22:37Z","timestamp":1669054957000},"page":"67-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Heart Failure in Rheumatic Disease"],"prefix":"10.1016","volume":"49","author":[{"given":"Brian Bridal","family":"L\u00f8gstrup","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2022.08.003_bib1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ejhf.483","article-title":"Comment on \u201cEpidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review","volume":"18","author":"van Riet","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"17","key":"10.1016\/j.rdc.2022.08.003_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"36","key":"10.1016\/j.rdc.2022.08.003_bib3","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.rdc.2022.08.003_bib4","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.jacc.2016.12.033","article-title":"Association Between Rheumatoid Arthritis and Risk of Ischemic and Nonischemic Heart Failure","volume":"69","author":"Mantel","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.rdc.2022.08.003_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/eci.12915","article-title":"Development of heart failure in patients with rheumatoid arthritis: A Danish population-based study","volume":"48","author":"L\u00f8gstrup","year":"2018","journal-title":"Eur J Clin Invest"},{"issue":"10","key":"10.1016\/j.rdc.2022.08.003_bib6","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1002\/art.21349","article-title":"How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease?","volume":"52","author":"Crowson","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2022.08.003_bib7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.20855","article-title":"The risk of congestive heart failure in rheumatoid arthritis: A population-based study over 46 years","volume":"52","author":"Nicola","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"24","key":"10.1016\/j.rdc.2022.08.003_bib8","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1016\/j.jacc.2017.10.028","article-title":"Heart Failure and Ischemic Heart Disease in Patients With Rheumatoid Arthritis","volume":"70","author":"L\u00f8gstrup","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"September 2020","key":"10.1016\/j.rdc.2022.08.003_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejim.2020.11.002","article-title":"Prevalence, risk factors and proteomic bioprofiles associated with heart failure in rheumatoid arthritis: The RA-HF study","volume":"85","author":"Ferreira","year":"2021","journal-title":"Eur J Intern Med"},{"issue":"9","key":"10.1016\/j.rdc.2022.08.003_bib10","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1161\/01.CIR.0000054612.26458.B2","article-title":"Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis","volume":"107","author":"Solomon","year":"2003","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.rdc.2022.08.003_bib11","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.24836","article-title":"Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study","volume":"61","author":"Peters","year":"2009","journal-title":"Arthritis Care Res"},{"issue":"6","key":"10.1016\/j.rdc.2022.08.003_bib12","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1002\/ehf2.12947","article-title":"Incidence of congestive heart failure in rheumatoid arthritis: a review of literature and meta-regression analysis","volume":"7","author":"Khalid","year":"2020","journal-title":"ESC Hear Fail"},{"issue":"5","key":"10.1016\/j.rdc.2022.08.003_bib13","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/14712598.2018.1462794","article-title":"The effect of biological DMARDs on the risk of congestive heart failure in rheumatoid arthritis: a systematic review","volume":"18","author":"Baniaamam","year":"2018","journal-title":"Expert Opin Biol Ther"},{"issue":"8","key":"10.1016\/j.rdc.2022.08.003_bib14","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/art.39195","article-title":"Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: A consortium of rheumatology researchers of North America registry study","volume":"67","author":"Solomon","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"26","key":"10.1016\/j.rdc.2022.08.003_bib15","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.rdc.2022.08.003_bib16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4065\/74.3.275","article-title":"Cardiac involvement in systemic lupus erythematosus","volume":"74","author":"Moder","year":"1999","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.rdc.2022.08.003_bib17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/heartjnl-2016-309561","article-title":"Incidence and risk of heart failure in systemic lupus erythematosus","volume":"103","author":"Kim","year":"2017","journal-title":"Heart"},{"issue":"3","key":"10.1016\/j.rdc.2022.08.003_bib18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.semarthrit.2019.06.005","article-title":"Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients","volume":"49","author":"Chen","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2022.08.003_bib19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.tcm.2017.08.015","article-title":"Heart failure in systemic lupus erythematosus","volume":"28","author":"Dhakal","year":"2018","journal-title":"Trends Cardiovasc Med"},{"issue":"14","key":"10.1016\/j.rdc.2022.08.003_bib20","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jacc.2021.02.029","article-title":"Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus","volume":"77","author":"Yafasova","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.rdc.2022.08.003_bib21","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/oxfordjournals.aje.a009122","article-title":"Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham study","volume":"145","author":"Manzi","year":"1997","journal-title":"Am J Epidemiol"},{"issue":"3","key":"10.1016\/j.rdc.2022.08.003_bib22","first-page":"141","article-title":"Outcome in Systemic Lupus Erythematosus - A prospective Study of Patients from a Defined Population","volume":"68","author":"Jonsson","year":"1989","journal-title":"Medicne"},{"issue":"2","key":"10.1016\/j.rdc.2022.08.003_bib23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3340\/jkns.2018.0110","article-title":"Association of Congestive Heart Failure and Death with Ankylosing Spondylitis : A Nationwide Longitudinal Cohort Study in Korea","volume":"62","author":"Bae","year":"2019","journal-title":"J\u00a0Korean Neurosurg Soc"},{"issue":"11","key":"10.1016\/j.rdc.2022.08.003_bib24","first-page":"2167","article-title":"Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"33","author":"Han","year":"2006","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2022.08.003_bib25","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2174\/1381612824666180123102632","article-title":"Inflammatory Arthritis and Heart Disease","volume":"24","author":"Castaneda","year":"2018","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.rdc.2022.08.003_bib26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.semarthrit.2014.02.004","article-title":"Diastolic left ventricular dysfunction in ankylosing spondylitis--a systematic review and meta-analysis","volume":"44","author":"Heslinga","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2022.08.003_bib27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2796.2010.02310.x","article-title":"Psoriasis is associated with clinically significant cardiovascular risk: A Danish nationwide cohort study","volume":"270","author":"Ahlehoff","year":"2011","journal-title":"J\u00a0Intern Med"},{"issue":"8","key":"10.1016\/j.rdc.2022.08.003_bib28","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/acr.24578","article-title":"Incidence of and Risk Factors for Heart Failure in Patients With Psoriatic Disease: A Cohort Study","volume":"74","author":"Koppikar","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"10.1016\/j.rdc.2022.08.003_bib29","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ejhf.113","article-title":"Psoriasis and risk of heart failure: a nationwide cohort study","volume":"16","author":"Khalid","year":"2014","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.rdc.2022.08.003_bib30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.7812\/TPP\/07-141","article-title":"Associations of psoriatic arthritis and cardiovascular conditions in a large population","volume":"12","author":"Kondratiouk","year":"2008","journal-title":"Perm J"},{"issue":"7","key":"10.1016\/j.rdc.2022.08.003_bib31","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/ard.2008.094839","article-title":"Cardiovascular morbidity in psoriatic arthritis","volume":"68","author":"Gladman","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2022.08.003_bib32","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s10067-019-04528-y","article-title":"Cardiac and cardiovascular morbidities in patients with psoriatic arthritis: a population-based case control study","volume":"38","author":"Kibari","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2022.08.003_bib33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/acr.22926","article-title":"Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"2","key":"10.1016\/j.rdc.2022.08.003_bib34","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11926-011-0234-2","article-title":"Association between gout and all-cause as well as cardiovascular mortality: A systematic review","volume":"14","author":"Lottmann","year":"2012","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"10.1016\/j.rdc.2022.08.003_bib35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13075-020-02175-2","article-title":"Gout is associated with an increased risk for incident heart failure among older adults: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort study","volume":"22","author":"Colantonio","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.rdc.2022.08.003_bib36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/eurjhf\/hft132","article-title":"Uric acid and risk of heart failure: A systematic review and meta-analysis","volume":"16","author":"Huang","year":"2014","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.rdc.2022.08.003_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2011-000282","article-title":"Gout and the risk for incident heart failure and systolic dysfunction","volume":"2","author":"Krishnan","year":"2012","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.rdc.2022.08.003_bib38","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.numecd.2019.12.008","article-title":"Asymptomatic hyperuricemia and incident congestive heart failure in elderly patients without comorbidities","volume":"30","author":"Wu","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"5","key":"10.1016\/j.rdc.2022.08.003_bib39","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/art.30239","article-title":"Low frequency of primary lipid screening among Medicare patients with rheumatoid arthritis","volume":"63","author":"Bartels","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2022.08.003_bib40","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/ard.2009.115717","article-title":"Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: Evidence for substantial undertreatment of lipid-associated cardiovascular risk?","volume":"69","author":"Toms","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2022.08.003_bib41","first-page":"777","article-title":"Comparison of cardiovascular risk algorithms in patients with vs without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis","volume":"56","author":"Alemao","year":"2017","journal-title":"Rheumatol (United Kingdom)"},{"issue":"10","key":"10.1016\/j.rdc.2022.08.003_bib42","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1002\/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I","article-title":"Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus","volume":"44","author":"Esdaile","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.rdc.2022.08.003_bib43","first-page":"1210","article-title":"Marked underdiagnosis and undertreatment of hypertension and hypercholesterolaemia in rheumatoid arthritis","volume":"55","author":"Van Breukelen-van der Stoep","year":"2016","journal-title":"Rheumatol (United Kingdom)"},{"issue":"4","key":"10.1016\/j.rdc.2022.08.003_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009134","article-title":"Multifactorial intervention to prevent cardiovascular disease in patients with early rheumatoid arthritis: Protocol for a multicentre randomised controlled trial","volume":"6","author":"Svensson","year":"2016","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.rdc.2022.08.003_bib45","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A\u00a0novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.rdc.2022.08.003_bib46","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/CIRCHEARTFAILURE.109.931451","article-title":"Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction","volume":"4","author":"Westermann","year":"2011","journal-title":"Circ Hear Fail"},{"issue":"4","key":"10.1016\/j.rdc.2022.08.003_bib47","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11897-017-0337-9","article-title":"Inflammation \u2013 Cause or Consequence of Heart Failure or Both?","volume":"14","author":"Van Linthout","year":"2017","journal-title":"Curr Heart Fail Rep"},{"issue":"6020","key":"10.1016\/j.rdc.2022.08.003_bib48","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1126\/science.1200708","article-title":"Transient Regenerative Potential of the Neonatal Mouse Heart","volume":"331","author":"Porrello","year":"2011","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.rdc.2022.08.003_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41536-021-00118-2","article-title":"Immunomodulation for optimal cardiac regeneration: insights from comparative analyses","volume":"6","author":"Farache Trajano","year":"2021","journal-title":"Npj Regen Med"},{"issue":"3","key":"10.1016\/j.rdc.2022.08.003_bib50","first-page":"e003688","article-title":"Activated T-Lymphocytes are Essential Drivers of Pathological Remodeling in Ischemic Heart Failure","volume":"10","author":"Bansal","year":"2017","journal-title":"Circ Hear Fail"},{"key":"10.1016\/j.rdc.2022.08.003_bib51","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac153","article-title":"Adult T-cells impair neonatal cardiac regeneration","author":"Dolejsi","year":"2022","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.rdc.2022.08.003_bib52","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.devcel.2022.01.012","article-title":"Heart regeneration: 20 years of progress and renewed optimism","volume":"57","author":"Garbern","year":"2022","journal-title":"Dev Cell"},{"issue":"5","key":"10.1016\/j.rdc.2022.08.003_bib53","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/0735-1097(95)00589-7","article-title":"Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD)","volume":"27","author":"Torre-Amione","year":"1996","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.rdc.2022.08.003_bib54","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1161\/01.CIR.103.16.2055","article-title":"Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone Trial (VEST)","volume":"103","author":"Deswal","year":"2001","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.rdc.2022.08.003_bib55","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Inflammation in Atherosclerosis. From Pathophysiology to Practice","volume":"54","author":"Libby","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10 SUPPL.1","key":"10.1016\/j.rdc.2022.08.003_bib56","article-title":"Role of Inflammation in Atherosclerosis Associated with Rheumatoid Arthritis","volume":"121","author":"Libby","year":"2008","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.rdc.2022.08.003_bib57","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0031-6997(24)01470-4","article-title":"The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system","volume":"52","author":"Elenkov","year":"2000","journal-title":"Pharmacol Rev"},{"issue":"16","key":"10.1016\/j.rdc.2022.08.003_bib58","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1093\/eurheartj\/ehr285","article-title":"Psoriasis and risk of atrial fibrillation and ischaemic stroke: A Danish Nationwide Cohort Study","volume":"33","author":"Ahlehoff","year":"2012","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.rdc.2022.08.003_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/lupus-2016-000189","article-title":"Assessing QT interval in patients with autoimmune chronic inflammatory diseases: Perils and pitfalls","volume":"3","author":"Lazzerini","year":"2016","journal-title":"Lupus Sci Med"},{"issue":"6","key":"10.1016\/j.rdc.2022.08.003_bib60","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1590\/S0104-42302012000600015","article-title":"Infliximab reduces cardiac output in rheumatoid arthritis patients without heart failure","volume":"58","author":"Santos","year":"2012","journal-title":"Rev Assoc Med Bras"},{"issue":"13","key":"10.1016\/j.rdc.2022.08.003_bib61","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted Anticytokine Therapy in Patients with Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.rdc.2022.08.003_bib62","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.semarthrit.2011.07.004","article-title":"Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: Comparison with control subjects from the multi-ethnic study of atherosclerosis","volume":"41","author":"Chung","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2022.08.003_bib63","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/ijcp.12382","article-title":"Anti-TNF-\u03b1 therapy for patients with sepsis: a systematic meta-analysis","volume":"68","author":"Lv","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.rdc.2022.08.003_bib64","doi-asserted-by":"crossref","first-page":"107961","DOI":"10.1016\/j.intimp.2021.107961","article-title":"Evaluation of adalimumab effects in managing severe cases of COVID-19 : A randomized controlled trial","volume":"99","author":"Fakharian","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"10.1016\/j.rdc.2022.08.003_bib65","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jacc.2019.01.005","article-title":"Heart Failure, the Inflammasome, and Interleukin-1\u03b2: Prognostic and Therapeutic?","volume":"73","author":"Everett","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.rdc.2022.08.003_bib66","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2022.08.003_bib67","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/FJC.0000000000000591","article-title":"Effect of Interleukin-1 Blockade on Left Ventricular Systolic Performance and Work: A Post-Hoc Pooled Analysis of Two Clinical Trials","volume":"72","author":"Buckley","year":"2018","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"10","key":"10.1016\/j.rdc.2022.08.003_bib68","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3899\/jrheum.131540","article-title":"Tocilizumab treatment increases left ventricular ejection fraction and decreases left ventricular mass index in patients with rheumatoid arthritis without cardiac symptoms: Assessed using 3.0 tesla cardiac magnetic resonance imaging","volume":"41","author":"Kobayashi","year":"2014","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2022.08.003_bib69","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/03009742.2017.1418424","article-title":"Impact of tocilizumab on N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis without cardiac symptoms","volume":"47","author":"Yokoe","year":"2018","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2022.08.003_bib70","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/ehf2.12487","article-title":"Utility and safety of tocilizumab in Takayasu arteritis with severe heart failure and muscle wasting","volume":"6","author":"Yano","year":"2019","journal-title":"ESC Hear Fail"},{"issue":"19","key":"10.1016\/j.rdc.2022.08.003_bib71","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1161\/CIRCULATIONAHA.120.053318","article-title":"Treatment Effects of Interleukin-6 Receptor Antibodies for Modulating the Systemic Inflammatory Response After Out-of-Hospital Cardiac Arrest (The IMICA Trial): A Double-Blinded, Placebo-Controlled, Single-Center, Randomized, Clinical Trial","volume":"143","author":"Meyer","year":"2021","journal-title":"Circulation"},{"issue":"9608","key":"10.1016\/j.rdc.2022.08.003_bib72","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(08)60134-8","article-title":"Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial","volume":"371","author":"Torre-Amione","year":"2008","journal-title":"Lancet (London, England)"},{"issue":"6","key":"10.1016\/j.rdc.2022.08.003_bib73","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jacc.2004.06.047","article-title":"Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial","volume":"44","author":"Torre-Amione","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.rdc.2022.08.003_bib74","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/01.HYP.25.3.343","article-title":"Glucocorticoids induce angiotensin-converting enzyme expression in vascular smooth muscle","volume":"25","author":"Fishel","year":"1995","journal-title":"Hypertens (Dallas, Tex 1979)"},{"issue":"18","key":"10.1016\/j.rdc.2022.08.003_bib75","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.rdc.2022.08.003_bib76","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.rdc.2022.08.003_bib77","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jchf.2019.04.022","article-title":"CORT-AHF Study: Effect on Outcomes of Systemic Corticosteroid Therapy During Early Management Acute Heart Failure","volume":"7","author":"\u00d2","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"3","key":"10.1016\/j.rdc.2022.08.003_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25030627","article-title":"TLR4-Targeting Therapeutics: Structural Basis and Computer-Aided Drug Discovery Approaches","volume":"25","author":"Ain","year":"2020","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.rdc.2022.08.003_bib79","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/1755-5922.12076","article-title":"Pentoxifylline in heart failure: A meta-analysis of clinical trials","volume":"32","author":"Champion","year":"2014","journal-title":"Cardiovasc Ther"},{"issue":"3","key":"10.1016\/j.rdc.2022.08.003_bib80","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1568-9972(03)00103-4","article-title":"Inflammation and chronic heart failure-potential therapeutic role of intravenous immunoglobulin","volume":"3","author":"Aukrust","year":"2004","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.rdc.2022.08.003_bib81","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.cardfail.2009.06.439","article-title":"The Effects of METhotrexate Therapy on the Physical Capacity of Patients With ISchemic Heart Failure: A Randomized Double-Blind, Placebo-Controlled Trial (METIS Trial)","volume":"15","author":"Moreira","year":"2009","journal-title":"J\u00a0Card Fail"},{"issue":"11","key":"10.1016\/j.rdc.2022.08.003_bib82","first-page":"1","article-title":"Interleukin-1 blockade in recently decompensated systolic heart failure: Results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial)","volume":"10","author":"Van Tassell","year":"2017","journal-title":"Circ Hear Fail"},{"issue":"2","key":"10.1016\/j.rdc.2022.08.003_bib83","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.amjcard.2013.08.047","article-title":"Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)","volume":"113","author":"Van Tassell","year":"2014","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.rdc.2022.08.003_bib84","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.amjcard.2018.07.002","article-title":"Usefulness of Canakinumab to Improve Exercise Capacity in Patients With Long-Term Systolic Heart Failure and Elevated C-Reactive Protein","volume":"122","author":"Trankle","year":"2018","journal-title":"Am J Cardiol"},{"issue":"25","key":"10.1016\/j.rdc.2022.08.003_bib85","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-\u03b1, in patients with moderate-to-severe heart failure: Results of the anti-TNF therapy against congestive heart failure (ATTACH","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.rdc.2022.08.003_bib86","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","article-title":"Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study","volume":"131","author":"Givertz","year":"2015","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.rdc.2022.08.003_bib87","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.jacc.2008.01.068","article-title":"Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study","volume":"51","author":"Hare","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.rdc.2022.08.003_bib88","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pharmthera.2013.12.013","article-title":"Targeting NOS as a therapeutic approach for heart failure","volume":"142","author":"Tang","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"9645","key":"10.1016\/j.rdc.2022.08.003_bib89","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet (London, England)"},{"issue":"22","key":"10.1016\/j.rdc.2022.08.003_bib90","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.rdc.2022.08.003_bib91","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jchf.2013.11.006","article-title":"Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study","volume":"2","author":"Deftereos","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10.1016\/j.rdc.2022.08.003_bib92","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/FJC.0000000000000931","article-title":"Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II-III Systolic Heart Failure","volume":"77","author":"Wohlford","year":"2020","journal-title":"J\u00a0Cardiovasc Pharmacol"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X22000722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X22000722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:31:38Z","timestamp":1760182298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X22000722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0889857X22000722"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2022.08.003","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heart Failure in Rheumatic Disease","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2022.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}